StudyFinder

Seasonal influenza vaccine high dose boosting in solid organ transplant recipients

Recruiting

We know that patients who have undergone a solid organ transplant are at higher risk for severe influenza infections and may not develop a robust antibody response to a single dose of the influenza vaccine. The purpose of this study is to better understand the body’s response to two doses of the high-dose influenza vaccine compared to one dose during an influenza season.

I'm interested

Male or Female
18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• at least 18 years old
• history of a solid organ transplant (liver, lung, heart, kidney, pancreas) at least 1 year before starting the study
Exclusion Criteria:

• women who are pregnant
• received ATG or carfilzomib in the past 3 months
• received rituximab or basiliximab in the past 3 months
• prednisone dose is greater than 20mg/ day
• history of a severe allergy to influenza vaccine (e.g., Guillain-Barré syndrome, anaphylaxis, or angioedema)
• have received the influenza vaccine for the current season

Drug: Fluzone High-Dose - 1 dose of HD, Drug: Fluzone High-Dose - 2 doses

Infectious Diseases

Clinics and Surgery Center (CSC), influenza, influenza vaccine, Solid organ transplant

Lauren Fontana - fonta125@umn.edu
Lauren Fontana
NA
STUDY00017687
See this study on ClinicalTrials.gov

Back